OneMedNet (ONMD) CMO and director reports stock purchases and 45,000 RSU grant

Rhea-AI Filing Summary

OneMedNet Corp insider activity: a director and Chief Medical Officer reported multiple open-market purchases of OneMedNet common stock between December 8, 2023 and January 30, 2024, generally in small increments at prices ranging from about $0.48 to $1.36 per share, some reported as weighted average prices from multiple trades. On January 19, 2024, the insider also received 45,000 restricted stock units (RSUs) as director compensation under the 2022 Equity Incentive Plan for board service in fiscal year 2024; each RSU represents one share of common stock and vested on December 31, 2024. Following these transactions, the insider reported owning 2,507,351 shares directly and 1,311,970 shares indirectly through a trust for children with an independent trustee, for which beneficial ownership is disclaimed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jeffrey

(Last) (First) (Middle)

6385 OLD SHADY OAK ROAD, SUITE 250

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OneMedNet Corp [ ONMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/08/2023		P		3,300	A	$1.31(1)	2,458,424	D
Common Stock	12/11/2023		P		30	A	$1.36(2)	2,458,454	D
Common Stock	12/12/2023		P		3,040	A	$1.06(3)	2,461,494	D
Common Stock	12/13/2023		P		50	A	$1.09	2,461,544	D
Common Stock	12/15/2023		P		10	A	$0.92	2,461,554	D
Common Stock	12/27/2023		P		10	A	$1.03	2,461,564	D
Common Stock	01/02/2024		P		20	A	$0.82	2,461,584	D
Common Stock	01/04/2024		P		180	A	$0.84(4)	2,461,764	D
Common Stock	01/08/2024		P		10	A	$0.83	2,461,774	D
Common Stock	01/09/2024		P		100	A	$0.86	2,461,874	D
Common Stock	01/10/2024		P		20	A	$0.85	2,461,894	D
Common Stock	01/12/2024		P		20	A	$0.81	2,461,914	D
Common Stock	01/16/2024		P		15	A	$0.75(5)	2,461,929	D
Common Stock	01/17/2024		P		362	A	$0.61(6)	2,462,291	D
Common Stock	01/19/2024		P		60	A	$0.48(7)	2,462,351	D
Common Stock	01/19/2024		A		45,000(15)	A	$0.00	2,507,351	D
Common Stock	01/22/2024		P		5,035	A	$0.49(8)	2,512,386	D
Common Stock	01/23/2024		P		720	A	$0.52(9)	2,513,106	D
Common Stock	01/24/2024		P		740	A	$0.55(10)	2,513,846	D
Common Stock	01/25/2024		P		2,304	A	$0.55(11)	2,516,150	D
Common Stock	01/26/2024		P		5,386	A	$0.56(12)	2,521,536	D
Common Stock	01/29/2024		P		950	A	$1.04(13)	2,522,486	D
Common Stock	01/30/2024		P		400	A	$1.14(14)	2,522,886	D
Common Stock								1,311,970	I	By trust for children(16)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.28 to $1.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.35 to $1.37, inclusive.

3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.09, inclusive.

4. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.82 to $0.85, inclusive.

5. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.71 to $0.78, inclusive.

6. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.56 to $0.73, inclusive.

7. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.44 to $0.62, inclusive.

8. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.44 to $0.62, inclusive.

9. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.48 to $0.54, inclusive.

10. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.52 to $0.60, inclusive.

11. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.50 to $0.60, inclusive.

12. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.51 to $0.60, inclusive.

13. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.07, inclusive.

14. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.48, inclusive.

15. Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

16. The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.

	/s/ Robert Golden, Attorney-in-Fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did OneMedNet Corp (ONMD) report in this Form 4?

The filing shows a OneMedNet director and Chief Medical Officer made a series of open-market purchases of common stock from December 8, 2023 through January 30, 2024, plus received a grant of 45,000 RSUs as director compensation.

At what prices did the OneMedNet (ONMD) insider buy shares?

The insider’s reported purchases were at prices generally between about $0.48 and $1.36 per share. Many prices are disclosed as weighted averages based on multiple trades within specified ranges, such as $1.28–$1.31 or $0.44–$0.62 per share.

How many restricted stock units did the OneMedNet (ONMD) insider receive?

The insider received 45,000 restricted stock units (RSUs) on January 19, 2024 as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan for board service in fiscal year 2024. Each RSU represents the right to receive one share of common stock and vested on December 31, 2024.

How many OneMedNet (ONMD) shares does the insider own after these transactions?

After the reported transactions, the insider directly owns 2,507,351 shares of OneMedNet common stock. In addition, 1,311,970 shares are held indirectly by a trust for children with an independent trustee, for which the insider disclaims beneficial ownership.

What is the insider’s role and relationship to OneMedNet Corp (ONMD)?

The reporting person is both a director and an officer of OneMedNet Corp, serving as Chief Medical Officer. The Form 4 is filed as a single reporting person filing.

What does the trust-related indirect ownership in OneMedNet (ONMD) represent?

The filing states that 1,311,970 shares are held by a trust for children with an independent trustee. The insider has no investment control over these shares and disclaims beneficial ownership, noting that the report should not be deemed an admission of beneficial ownership for Section 16 or any other purpose.

How are the weighted average prices in the OneMedNet (ONMD) Form 4 explained?

Several footnotes explain that prices in Column 4 are weighted average prices for multiple transactions executed within stated price ranges, for example $0.71–$0.78 or $1.03–$1.48. The insider undertakes to provide full trade-by-trade detail to the issuer, any shareholder, or SEC staff upon request.